Liminal BioSciences buys Fairhaven, secures VC investment
Liminal BioSciences, a Laval, Quebec-based clinical-stage biopharmaceutical company, has acquired Fairhaven Pharmaceuticals, a developer of small molecule, oral therapeutics for severe inflammatory conditions, for C$8 million in shares.
20 July 2020•7 mins read
